Clinical trials: Pancreas Tumor
Pancreatic Cancer
Using Digestive Microbial Information to Enhance the Early Detection of Pancreatic Cancer
Pancreatic cancer (PCA) is a leading death-related cancer. There is an urgent need for accurate, noninvasive diagnostic options in the early detection of pancreatic cancer (PCA), since delayed diagnosis increases the risk of…
- Trial name
- NCT05689138
- Testing
- Oral and Fecal Sample Collection
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Ovarian Cancer
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers.
- Conditions
- Breast Cancer, Ovarian Cancer, Lung Cancer, Gastric Cancer
- Trial name
- NCT02713984
- Testing
- Anti-HER2 CAR-T
- Where
- China
- Sponsor
- Zhi Yang
Neoplasms Pancreatic
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery
- Trial name
- PRIMUS002 (NCT04176952)
- Testing
- FOLFOX-A, AG
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Judith Dixon-Hughes
Neoplasms, Pancreatic Neoplasms
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
- Trial name
- NCT00102752
- Testing
- Glufosfamide, Gemcitabine
- Where
- 9 sites in United States, Brazil
- Volunteers
- 47 people
- Sponsor
- Threshold Pharmaceuticals
Pancreatic Cancer
Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses
Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to…
- Trial name
- NCT01703026
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- Changi General Hospital
Pancreatic Cancer, Liver Metastases
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
To explore the clinical characteristics of pancreatic cancer patients with liver metastases who can benefit from surgery, and to develop evaluation criteria for surgical indications, so as to provide basis for comprehensive…
- Conditions
- Pancreatic Cancer, Liver Metastases, Surgery, Adjuvant Therapy
- Trial name
- PCLM:CSSG (NCT06873178)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- China-Japan Friendship Hospital
Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel.
- Conditions
- Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- BRAVE (NCT07714538)
- Where
- 6 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Insulinoma, Nesidioblastosis
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients.
- Trial name
- NCT02560376
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
This multicentric open-label trial will compare the efficacy and safety of stereotactic body radiation therapy (SBRT) followed by NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) vs NALIRIFOX…
- Trial name
- NCT06259058
- Testing
- Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Functioning Entero-pancreatic Endocrine Tumour
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28…
- Trial name
- NET729 (NCT00842348)
- Testing
- lanreotide (Autogel formulation)
- Where
- 25 sites in United States, Belgium and 7 more
- Volunteers
- 89 people
- Sponsor
- Ipsen
Pancreatic Cancer, Cholangiocarcinoma
Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures
Malignant bile duct obstruction is a common sequela of pancreatic cancers or distal bile duct cancers, and its development can hinder the use of chemotherapy, decrease patient quality of life, and decrease survival.
- Trial name
- NCT01721174
- Testing
- SEMS only, EBRFA and SEMS
- Where
- Hong Kong
- Volunteers
- 42 people
- Sponsor
- Chinese University of Hong Kong
Pancreatic Neoplasm
A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients
Radiation therapy improves cancer cure rates by killing cancer cells but it also contributes to long-term side effects in cancer survivors by unintentionally damaging normal organs such as the intestine.
- Trial name
- XACT-PANC-2 (NCT03541486)
- Testing
- Ascorbate, Gemcitabine, radiation therapy
- Where
- United States
- Sponsor
- Joseph J. Cullen, MD, FACS
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where…
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic
- Trial name
- NCT05074472
- Testing
- ZB131
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- ZielBio, Inc.
Pancreatic Cancer, Pancreatic Adenocarcinoma
Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma
There is a need for better visualization of resection margins and detection of small tumor deposits during surgery for pancreatic cancer.
- Trial name
- PENGUIN (NCT02743975)
- Testing
- Bevacizumab-800CW
- Where
- 3 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Pancreatic Neoplasms
The Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy)
Main objective: This project intends to design a simulated RCT project and clinically relevant RCT study to target, selecting the study titled "Short-Term outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in…
- Trial name
- TDCBLAP (NCT06685939)
- Testing
- LPD
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhijun Bao
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
In Europe, pancreatic cancer (PC) is the 7th most common cancer and the 5th leading cause of cancer death in Europe. Each year, the number of deaths due to prostate cancer is almost as high as the number of new cases diagnosed…
- Trial name
- FUNGEMAX (NCT03693677)
- Testing
- Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel
- Where
- 36 sites in France, Martinique
- Volunteers
- 288 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.